Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine

Colloids and Surfaces B: Biointerfaces

Volumn 101, Issue , 2013, Pages 510-516

  Barwal, Indu ^a   Sood, Anil ^a   Sharma, Mohit ^a   Singh, Bikram ^a   Yadav, Subhash C ^a  

^a CSIR INSTITUTE OF HIMALAYAN BIORESOURCE TECHNOLOGY   (India)

Author keywords

Antidiabetic; Control release; Nanoencapsulation; PLA; Pluronic F 68; Stevioside

Indexed keywords

ANTIDIABETIC; CONTROL RELEASE; NANO-ENCAPSULATION; PLA; PLURONIC-F-68; STEVIOSIDES;

BIOCHEMISTRY; COPOLYMERS; LOADING; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

PATHOGENS;

POLOXAMER; POLYLACTIDE; STEVIOSIDE;

ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG FORMULATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTESTINE ABSORPTION; NANOMEDICINE; NANOPHARMACEUTICS; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SUSTAINED DRUG RELEASE;

BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DITERPENES, KAURANE; DRUG COMPOUNDING; EXCIPIENTS; GLUCOSIDES; HYPOGLYCEMIC AGENTS; INDICATORS AND REAGENTS; INTESTINAL ABSORPTION; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; POLYESTERS; POLYMERS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84866546076     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.07.005     Document Type: Article

References (70)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Horenstein R.B., Shuldiner A.R. Genetics of diabetes. Rev. Endocr. Metab. Disord. 2004, 5:25-36.
3. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
4. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
5. Mohan V., Sandeep S., Deepa R., Shah B., Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J. Med. Res. 2007, 125:217-230.
6. Akiyama S., Katsumata S., Suzuki K., Nakaya Y., Ishimi Y., Uehara M. Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes. Biosci. Biotechnol. Biochem. 2009, 73:2779-2782.
7. Brahmachari G. Bio-flavonoids with promising antidiabetic potentials: a critical survey. Challenge 2011, 661:187-212.
8. Narender T., Khaliq T., Madhur G. Naturally occurring antihyperglycemic and antidyslipidemic agents. Steroids 2011, 661:155-185.
9. Choi M.S., Jung U.J., Yeo J., Kim M.J., Lee M.K. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab. Res. Rev. 2008, 24:74-81.
10. Haraguchi H., Ohmi I., Fukuda A., Tamura Y., Mizutani K., Tanaka O., Chou W.H. Inhibition of aldose reductase and sorbitol accumulation by astilbin and taxifolin dihydroflavonols in Engelhardtia chrysolepis. Biosci. Biotechnol. Biochem. 1997, 61:651-654.
11. Akiyama S., Katsumata S., Suzuki K., Ishimi Y., Wu J., Uehara M. Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J. Clin. Biochem. Nutr. 2010, 46:87-92.
12. Vajo Z., Fawcett J., Duckworth W.C. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr. Rev. 2001, 22:706-717.
13. Bailey C.J., Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989, 12:553-564.
14. Thomson M., Al-amin Z.M., Al-qattan K.K., Shaban L.H., Ali M. Anti-diabetic and hypolipidaemic properties of garlic (Allium sativum) in streptozotocin-induced diabetic rats. Am. J. Clin. Nutr. 2007, 15:108-115.
15. Chaturvedi A., Bhawani G., Agarwal P.K., Goel S., Singh A., Goel R.K. Antidiabetic and antiulcer effects of extract of Eugenia jambolana seed in mild diabetic rats: study on gastric mucosal offensive acid-pepsin secretion. Indian J. Physiol. Pharmacol. 2009, 53:137-146.
16. Sharma V.K., Kumar S., Patel H.J., Hugar S. Hypoglycemic activity of Ficus glomerata in alloxan induced diabetic rats. Int. J. Pharma. Sci. Rev. Res. 2010, 1:18-22.
17. Tongia A., Tongia S.K., Dave M. Phytochemical determination and extraction of momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J. Physiol. Pharmacol. 2004, 48:241-244.
18. Tembhurne S.V., Sakarkar D.M. Influence of Murraya koenigii on experimental model of diabetes and progression of neuropathic pain. Res. Pharm. Sci. 2010, 5:41-47.
19. Vinuthan M.K., Girish Kumar V., Ravindra J.P., Jayaprakash, Narayana K. Effect of extracts of Murraya koenigii leaves on the levels of blood glucose and plasma insulin in alloxan-induced diabetic rats. Indian J. Physiol. Pharmacol. 2004, 48:348-352.
20. Prasad S.K., Kulshreshtha A., Qureshi T.N. Antidiabetic activity of some herbal plants in streptozotocin induced diabetic albino rats. Diabetes 2009, 8:551-557.
21. Biswas M K.B., Bhattacharya S., Kumar R.B., Ghosh A.K., Haldar P.K. Antihyperglycemic activity and antioxidant role of Terminalia arjuna leaf in streptozotocin-induced diabetic rats. Pharm. Biol. 2011, 49:335-340.
22. Thirumalai T., Therasa S.V., Elumalai E., David E. Hypoglycemic effect of Brassica juncea (seeds) on streptozotocin induced diabetic male albino rat. Asian Pacific J. Trop. Biomed. 2011, 323-325.
23. Jung M., Park M., Lee H.C., Kang Y.H., Kang E.S., Kim S.K. Antidiabetic agents from medicinal plants. Curr. Med. Chem. 2006, 13:1203-1218.
24. Geuns J.M. Stevioside. Phytochemistry 2003, 64:913-921.
25. Goyal S.K., Samsher, Goyal R.K. Stevia (Stevia rebaudiana) a bio-sweetener: a review. Int. J. Food Sci. Nutr. 2010, 61:1-10.
26. Jeppesen P.B., Gregersen S., Alstrup K.K., Hermansen K. Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats. Phytomedicine 2002, 9:9-14.
27. Kujur R.S., Singh V., Ram M., Yadava H.N., Singh K.K., Kumari S., Roy B.K. Antidiabetic activity and phytochemical screening of crude extract of Stevia rebaudiana in alloxan-induced diabetic rats. Pharmacognosy Res. 2010, 2:258-263.
28. J. K. Kumar, G.D. Kiran Babu, V.K. Kaul and P.S. Ahuja. A process for the production of steviosides from Stevia rebaudiana Bertoni. Korea International property Rights, Patent No. 10-0944242/KR, (2010).
29. Megeji N.W., Kumar J.K., Singh V., Kaul V.K., Ahuja P.S. Introducing Stevia rebaudiana, a natural zero-calorie sweetener. Curr. Sci. 2005, 88:801-804.
30. Hanson J.R., De Oliveira B.H. Stevioside and related sweet diterpenoid glycosides. Nat. Prod. Rep. 1993, 10:301-309.
31. +-channel activity. Metabolism 2000, 49:208-214.
32. Soejarto D.D., Kinghorn A.D., Farnsworth N.R. Potential sweetening agents of plant origin. III. Organoleptic evaluation of Stevia leaf herbarium samples for sweetness. J. Nat. Prod. 1983, 45:590-598.
33. Kinghorn A.D., Soejarto D.D. Alternative Sweetners 1991, Marcel Dekker, New York. 2nd ed.
34. Lailerd N., Saengsirisuwan V., Sloniger J.A., Toskulkao C., Henriksen E.J. Effects of stevioside on glucose transport activity in insulin-sensitive and insulin-resistant rat skeletal muscle. Metabolism 2004, 53:101-107.
35. Suanarunsawat T., Chaiyabutr N. The effect of stevioside on glucose metabolism in rat. Can. J. Physiol. Pharmacol. 1997, 75:976-982.
36. Melis M.S. Chronic administration of aqueous extract of Stevia rebaudiana in rats: renal effects. J. Ethnopharmacol. 1995, 47:129-134.
37. Chen J., Jeppesen P.B., Nordentoft I., Hermansen K. Stevioside counteracts the glyburide-induced desensitization of the pancreatic beta-cell function in mice: studies in vitro. Metabolism 2006, 55:1674-1680.
38. Gregersen S., Jeppesen P.B., Holst J.J., Hermansen K. Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Metabolism 2004, 53:73-76.
39. Chen T.H., Chen S.C., Chan P., Chu Y.L., Yang H.Y., Cheng J.T. Mechanism of the hypoglycemic effect of stevioside, a glycoside of Stevia rebaudiana. Planta Med. 2005, 71:108-113.
40. Matsui M., Matsui K., Kawasaki Y., Oda Y., Noguchi T., Kitagawa Y., Sawada M., Hayashi M., Nohmi T., Yoshihira K., Ishidate M., Sofuni T. Evaluation of the genotoxicity of stevioside and steviol using six in vitro and one in vivo mutagenicity assays. Mutagenesis 1996, 11:573-579.
41. Suttajit M., Vinitketkaumnuen U., Meevatee U., Buddhasukh D. Mutagenicity and human chromosomal effect of stevioside, a sweetener from Stevia rebaudiana Bertoni. Environ. Health Perspect. 1993, 101(Suppl. 3):53-56.
42. Totte N., Charon L., Rohmer M., Compernolle F., Baboeuf I., Geuns J. Biosynthesis of the diterpenoid steviol an ent-kaurene derivative from Stevia rebaudiana Bertoni, via the methylerythritol phosphate pathway. Tetrahedron Lett. 2000, 41:6407-6410.
43. 131I-stevioside and its metabolites. Nucl. Med. Biol. 1996, 23:97-100.
44. Gardana C., Simonetti P., Canzi E., Zanchi R., Pietta P. Metabolism of stevioside and rebaudioside A from Stevia rebaudiana extracts by human microflora. J. Agric. Food Chem. 2003, 51:6618-6622.
45. Geuns J.M., Buyse J., Vankeirsbilck A., Temme E.H. Metabolism of stevioside by healthy subjects. Exp. Biol. Med. (Maywood) 2007, 232:164-173.
46. Koyama E., Kitazawa K., Ohori Y., Izawa O., Kakegawa K., Fujino A., Ui M. In vitro metabolism of the glycosidic sweeteners, stevia mixture and enzymatically modified stevia in human intestinal microflora. Food Chem. Toxicol. 2003, 41:359-374.
47. Koyama E., Sakai N., Ohori Y., Kitazawa K., Izawa O., Kakegawa K., Fujino A., Ui M. Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, steviol, in rats and humans. Food Chem. Toxicol. 2003, 41:875-883.
48. Boonkaewwan C., Toskulkao C., Vongsakul M., Anti-inflammatory immunomodulatory activities of stevioside and its metabolite steviol on THP-1 cells. J. Agric. Food Chem. 2006, 54:785-789.
49. Xili L., Chengjiany B., Eryi X., Reiming S., Yuengming W., Haodong S., Zhiyian H. Chronic oral toxicity and carcinogenicity study of stevioside in rats. Food Chem. Toxicol. 1992, 30:957-965.
50. Geuns J.M., Augustijns P., Mols R., Buyse J.G., Driessen B. Metabolism of stevioside in pigs and intestinal absorption characteristics of stevioside, rebaudioside A and steviol. Food Chem. Toxicol. 2003, 41:1599-1607.
51. Geuns J.M., Malheiros R.D., Moraes V.M., Decuypere E.M., Compernolle F., Buyse J.G. Metabolism of stevioside by chickens. J. Agric. Food Chem. 2003, 51:1095-1101.
52. Geuns J.M.C. Safety evaluation of stevia and stevioside. Studies in Natural Products Chemistry 2002, vol. 27. Elsevier, Amsterdam, pp. 299-319.
53. Huxtable R. Pharmacology and Toxicology of Stevioside, Rebaudioside A, and Steviol 2002, Taylor and Francis, London and NY.
54. Toskulkao C., Sutheerawatananon M., Wanichanon C., Saitongdee P., Suttajit M. Effects of stevioside and steviol on intestinal glucose absorption in hamsters. J. Nutr. Sci. Vitaminol. (Tokyo) 1995, 41:105-113.
55. Wingard R.E., Brown J.P., Enderlin F.E., Dale J.A., Hale R.L., Seitz C.T. Intestinal degradation and absorption of the glycosidic sweeteners stevioside and rebaudioside A. Experientia 1980, 36:519-520.
56. De Campos A.M., Sanchez A., Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 2001, 224:159-168.
57. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., Maitra A. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J. Nanobiotechnol. 2007, 5:3.
58. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28:5-24.
59. Vert M., Schwach G., Engel R., Coudane J. Something new in the field of PLA/GA bioresorbable polymers?. J. Control. Release 1998, 53:85-92.
60. Santander-Ortega M.J., Jodar-Reyes A.B., Csaba N., Bastos-Gonzalez D., Ortega-Vinuesa J.L. Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J. Colloid Interface Sci. 2006, 302:522-529.
61. Palomares L.A., Gonzalez M., Ramirez O.T. Evidence of Pluronic F-68 direct interaction with insect cells: impact on shear protection, recombinant protein, and baculovirus production. Enzyme Microb. Technol. 2000, 26:324-331.
62. Tharmalingam T., Ghebeh H., Wuerz T., Butler M. Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol. Biotechnol. 2008, 39:167-177.
63. Vinogradov S.V., Kohli E., Zeman A.D. Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates. Pharm. Res. 2006, 23:920-930.
64. Yadav S.C., Yadav S.K., Sood A., Sharma M., Singh B. Development of antidiabetic nanomedicine from stevioside. J. Biomed. Nanotechnol. 2011, 7:54-55.
65. Peltonen L., Aitta J., Hyvonen S., Karjalainen M., Hirvonen J. Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech 2004, 5:E16.
66. Inamake M.R., Shelar P., Kulkarni M., Katekar S., Tambe R. Isolation and analytical characterization of stevioside from leaves of Stevia rebaudiana Bert; (Asteraceae). Int. J. Res. Ayurveda Pharm. 2010, 1:572-581.
67. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
68. Singh V., Chaudhary A.K. Development and characterization of rosiglitazone loaded gelatin nanoparticles using two step desolvation method. Int. J. Pharm. Sci. Rev. Res. 2010, 5:100-103.
69. McClean S., Prosser E., Meehan E., O'Malley D., Clarke N., Ramtoola Z., Brayden D. Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. 1998, 6:153-163.
70. Xing J., Zhang D., Tan T. Studies on the oridonin-loaded poly(d,l-lactic acid) nanoparticles in vitro and in vivo. Int. J. Biol. Macromol. 2007, 40:153-158.